Reflux esophagitis
Conditions
Interventions
Changing of proton pump inhibitor from ransoprazole to omeprazole.
Sponsors
Department of Gastroenterology and Hepatology, Kansai Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who can give a written consent to the entry of the study. (2) Patients of 20 years old and over without distinction of gender. (3) Patients who were diagnosed as having reflux esophagitis (Grade M to D). (4) Patients who are taking ransoprazole 15mg or 30mg per day for more than 2 months. (5) Patients whose symptoms are more than 8 points by F scale evaluation.
Exclusion criteria
Exclusion criteria: (1) Patients who are under 20 years of age. (2) Patients who are allergic to the ingredient of the test drugs. (3) Patients who underwent an operation of intestinal resection or vagotomy. (4) Patients who have alert symptoms such as nausea, gastrointestinal bleeding and rapid body weight loss. (5). Patients who had previous medical history of or suffer from the following diseases:Zollinger-Ellison syndrome, inflammatory bowel disease, irritable bowel disease, esophageal stenosis, esophageal achalasia, malabsorption, cerebrovascular disease such as cerebral hemorrhage, cerebral infarction. (6) Patient who can not participate the study due to the coexistence of the diseases such as severe liver, renal or heart diseases. (7) Patients who have malignancy or suspected malignancy (Cured patients are eligible). (8) Patients who are pregnant, in breast-feeding, or may be pregnant. (9) Patients who need continuous medication with drugs that are contraindication or dangerous to the combination with the test drug. (10) Patients who take proton pump inhibitors except ransoprazole. (11) Patients who take drugs that may affect the evaluation of the test drug (Patients who take such drugs without changing the usage or doses during the study period are eligible). (12) Patients who are not considered to be eligible for the study by the doctor's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment effect of omeprazole for patients with reflux esophagitis who are refractory to treatment with ransoprazole. | — |
Countries
Japan
Contacts
Public ContactAkiyoshi Nishio
Department of Gastroenterology and Hepatology Takii Hospital, Kansai Medical University
Outcome results
None listed